Life Science INNvestor Reports

The life science industry holds diverse avenues of opportunity for investors, and INN has assembled a collection of free reports for those interested in jumping into this exciting space. With topics ranging from biotech to medical devices, our coverage can help you make the right decisions with your money.


 Life Science & Healthcare Investing


Life Science & Healthcare Investing

From diagnostics to drug development, the genetics industry provides information that biotechnology, pharmaceutical and medical device companies need to continue making innovative products. INN has compiled an overview of each sector to help you make informed investment decisions. Access your report for FREE.


Psychedelics Investing Free Report

Start Here — Investing in Psychedelics

Market watchers agree that the psychedelic medicine sector is growing, and a variety of companies are set to enter this early stage public space. Read our FREE report to learn about the new and exciting psychedelics investing market!


 Psychedelics Outlook – Plotting a New Course

Psychedelics Outlook – Plotting a New Course

The idea of investing in a psychedelic drug company may have sounded unlikely before 2020. But now investors are enjoying the dawn of a new alternative drug market that is trying to capitalize on the medical benefits of psychedelic substances. Lots of questions? Get our INNvestor Outlook Report Psychedelics Outlook – Plotting a New Course


Genetics Investing Free Report

Start Here — Investing in Genetics

The CRISPR-Cas9 technology is revolutionary new technology and changing what’s possible with genetics. How do you profit from it? Download our Genetics INNvestor Report today!


Coronavirus Investing: An Overview for Investors

Coronavirus Investing: An Overview for Investors

COVID-19 continues to impact markets across the world. Here’s an overview of INN’s content on coronavirus investing. INN has prepared a series of articles to catch our investor audience up on the biggest developments related to the pandemic and how the markets are moving.